Evidence map›Paper›PMID 36483739›Full record

ReviewFrontiers in pharmacology2022

New insight into the management of renal excretion and hyperuricemia: Potential therapeutic strategies with natural bioactive compounds.

Bendong Yang, Meiling Xin, Shufei Liang, Xiaoxue Xu, Tianqi Cai, Ling Dong, Chao Wang, Meng Wang, Yuting Cui, Xinhua Song and 2 more

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06084585 (A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06084585 naunknown statusnot on this mapstarted 2023, after this paper: background citation

A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

TypeinterventionalSponsorAmway (China) R&D CenterRan2023 to 2024Enrolled180ConditionsHyperuricemiaArmsStudy Product A (High-dose 2X), Study Product B (Low-dose X), Placebo
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Polyphenol-Rich Extract fromMolecules (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Bendong YangSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Meiling XinSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Shufei LiangSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Xiaoxue XuSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Tianqi CaiSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Ling DongSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Chao WangSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Meng WangSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Yuting CuiSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Xinhua SongSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Jinyue SunKey Laboratory of Novel Food Resources Processing, Ministry of Agriculture and Rural Affairs/Key Laboratory of Agro-Products Processing Technology of Shandong Province/Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences, Jinan, China.
Wenlong SunSchool of Life Sciences and Medicine, Shandong University of Technology, Zibo, China.
Shandong University of Technology · CNShandong Academy of Agricultural Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperuricemia is the result of increased production and/or underexcretion of uric acid. Hyperuricemia has been epidemiologically associated with multiple comorbidities, including metabolic syndrome, gout with long-term systemic inflammation, chronic kidney disease, urolithiasis, cardiovascular disease, hypertension, rheumatoid arthritis, dyslipidemia, diabetes/insulin resistance and increased oxidative stress. Dysregulation of xanthine oxidoreductase (XOD), the enzyme that catalyzes uric acid biosynthesis primarily in the liver, and urate transporters that reabsorb urate in the renal proximal tubules (URAT1, GLUT9, OAT4 and OAT10) and secrete urate (ABCG2, OAT1, OAT3, NPT1, and NPT4) in the renal tubules and intestine, is a major cause of hyperuricemia, along with variations in the genes encoding these proteins. The first-line therapeutic drugs used to lower serum uric acid levels include XOD inhibitors that limit uric acid biosynthesis and uricosurics that decrease urate reabsorption in the renal proximal tubules and increase urate excretion into the urine and intestine

Indexed as

chronic kidney diseasehyperuricemianatural productsrenal urate extractionurate transporters

Identifiers

PMID36483739
PMCPMC9723165
OpenAlexW4309699684

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.